Article
Recent research suggests that the common fusion of two genes may point to a molecular basis for prostate cancer.
Darolutamide is safe, efficacious in mHSPC regardless of patient age
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
STOPCAP: ARPIs benefit younger patients with mHSPC
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
UGN-101 associated with favorable long-term durability in low-grade UTUC
Mevrometostat/enzalutamide combo shows rPFS benefit in mCRPC